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Background: Carpal tunnel syndrome (CTS) is a common condition (prevalence of 4%) where the median nerve is
compressed within the carpal tunnel resulting in numbness, tingling, and pain in the hand. Current non-surgical
treatment options (oral medication, corticosteroid injections, splinting, exercise, and mobilization) show limited
effects, especially in the long-term. Carpal tunnel release (CTR) surgery is effective in 70 to 75% of patients, but is
relatively invasive and can be accompanied by complications. In an observational study, mechanical traction proved
to be effective in up to 70% of patients directly after treatment and in 60% after two years follow-up. This randomized
controlled trial (RCT) will examine the effectiveness of mechanical traction compared to care as usual in CTS.
Methods/Design: Patients diagnosed with CTS will be recruited from an outpatient neurology clinic and randomly
assigned to the intervention group (mechanical traction) or the control group (care as usual). Participants in the
intervention group will receive 12 treatments with mechanical traction during six consecutive weeks. Primary outcome
is symptom severity and functional status, which are measured with the Boston Carpel Tunnel Questionnaire (BCTQ).
Secondary outcomes are quality of life (WHOQOL-BREF), health related resource utilization, and absenteeism from work.
Outcomes will be assessed at baseline, and at 3, 6, and 12 months after inclusion. Linear mixed effect models will be
used to determine the change from baseline at 12 months on the BCTQ, WHOQOL-BREF, absenteeism from work and
health related resource utilization. The baseline measurement, change from baseline at three and six months, as well as
duration of symptoms until inclusion, age, gender, and co-morbidity will be included as covariates The Pearson’s
correlation coefficient will be generated to assess the correlation between depression and anxiety and treatment
outcome.
Discussion: Since current non-surgical treatment options are not effective long-term and CTR is relatively invasive,
there is a need for an effective and non-invasive treatment option. Mechanical traction is a safe treatment option that
may provide a good alternative for the usual care. Considering the prevalence of CTS, the study is of great clinical value
to a large patient population.
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Carpal tunnel syndrome (CTS) is a common compressive
neuropathy in which the median nerve is compressed at
the level of the carpal tunnel [1,2]. CTS can occur in one
or both hands, and is either idiopathic (spontaneous) or
dynamic (only during certain movements). The compres-
sion leads to numbness and tingling in the first three
fingers and the radial side of the ring finger, paresthesia,
pain, and (in severe cases) weakness. The symptoms are
often worse at night or after use of the hand [2]. Preva-
lence is estimated to be about 4% in the general popula-
tion [3] and up to 10% in the working population [4].
Although CTS can occur at any age, it most commonly
occurs between 40 to 60 years and its prevalence is higher
in women compared to men [1]. Obesity, diabetes melli-
tus, and alcohol abuse are risk factors for developing CTS
[1]. Occupation has been identified as an environmental
risk factor: vibration, hand force, and repetition are as-
sociated with increased risk for developing CTS [5].
Furthermore, there is a psychological component to
the experience of CTS symptoms: depression has been
reported as a predictor of pain in CTS patients [6].
CTS can be diagnosed using electromyography (EMG).
Compression of the median nerve can lead to damage and
dysfunction of the myelin sheath, resulting in slowed con-
duction velocity, which can be detected using EMG [7].
Treatment options to reduce the compression and relieve
symptoms can be roughly divided into surgical and non-
surgical procedures. Non-surgical, less invasive treatment
options are numerous, including oral medication, cortico-
steroid injections, splinting, exercise, and mobilization in-
terventions [8-12]. However, there is only short-term or
limited evidence of benefit for these interventions. Many
(non-steroidal) drugs did not prove to be significantly
superior compared to placebo [12]. There is only limited
evidence for the effectiveness of splinting, exercise, and
mobilization interventions [10,11]. Local corticosteroid in-
jections provide considerable symptom relief and therefore
show the best results of the non-surgical treatments [8,9].
However, corticosteroids seem to merely suppress CTS
symptoms and the positive effects do not last [8,13]. The
treatment effect diminishes over time and half of patients
who receive corticosteroid injections experience recur-
rence of symptoms within a year [13].
Compared to non-surgical treatment, surgery is the
only known treatment option that shows long-term posi-
tive effects [14]. The principle of the procedure, called
carpal tunnel release (CTR), is to decompress the nerve
by dividing the transverse carpal ligament [15]. Evidence
suggests that CTR is a more effective treatment for CTS
than splinting or oral medication, especially long-term
[15]. However, up to 30% of patients who underwent
CTR experience persistence or recurrence of CTS symp-
toms in the long-term or suffer from complications[16,17]. Therefore, there is still a clear need for an alter-
native non-invasive therapy, possibly making surgery
redundant for a sub-category of patients.
Another promising non-surgical treatment for CTS is
mechanical wrist traction using the Phystrac traction
device. The Phystrac applies repeated traction movements
to the wrist in different positions using gravitational force.
Brunarski et al. described four case studies using mechan-
ical traction that showed promising results [18]. In an
observational study, physical therapists reported a success
rate of 70% with mechanical traction immediately post-
treatment [19], and 60% after two years follow-up [20].
However, until now, no randomized controlled trial (RCT)
has been performed to show clinical evidence for the
effectiveness of mechanical traction as compared to care
as usual (surgical and non-surgical intervention).
Hypothesis and objectives
The purpose of this study is to evaluate the effectiveness
of mechanical traction in alleviating symptoms and
improving hand function in patients with CTS compared
to care as usual. The primary outcome is the change
from baseline in symptom severity and functional status
at 12 months, which is measured using the Boston Car-
pal Tunnel Questionnaire (BCTQ). Change from base-
line in functional status and symptom severity at three
and six months will be used as covariates. As secondary
outcomes, we will assess quality of life, health related re-
source utilization, and absenteeism from work. Tertiary
outcome is the impact of psychological distress on treat-
ment outcome. We hypothesize that hand function and
symptom severity will significantly improve more in
CTS patients receiving 12 treatments with mechanical
traction compared to CTS patients who receive care as
usual after 12 months. Moreover, 12 treatments with
mechanical traction will result in less absenteeism from
work, a higher quality of life, and less health related
resource utilization compared to care as usual in CTS
patients after 12 months follow-up. Furthermore, a
higher degree of depression and anxiety at baseline will
result in a lower treatment effect in CTS patients.
Methods/Design
Study design
This study is designed as an RCT. Eligible patients diag-
nosed with CTS will be recruited from the outpatient
neurology clinic of VieCuri Medical Center in Venlo,
The Netherlands. They will be randomly allocated to the
intervention (mechanical traction) or control (care as
usual) group. The intervention group will receive 12
treatments with mechanical traction using the Phystrac
traction device. The control group will receive care as
usual, which may involve an expectant strategy, splint-
ing, drug therapy, local corticosteroid injections or CTR.
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Adult men and women (aged 18 to 80 years) who have
been diagnosed with CTS by means of a positive EMG
will be invited to participate in our study. They have to
be physically able to visit the outpatient clinic twice a
week and sit in an upright position for at least 20 mi-
nutes. Patients with a previous history of CTS surgery
will be excluded as well as those with insufficient under-
standing of the Dutch language. In addition, patients
who have been diagnosed with another known (rare)
cause of neuropathy, or who are suffering from a severe
psychiatric disorder, such as personality disorder, schizo-
phrenia or bipolar disorder will also be excluded.
Recruitment, screening process and enrollment
Neurologists will select eligible patients based on the in-
and exclusion criteria. During the visit to the outpatient
clinic, the neurologist will inform patients about the study.
In addition, the patients will receive an information letter.
Two weeks after their visit to the outpatient clinic, they
will be phoned by the researcher and asked whether they
are interested to participate in the study. Eligible patients
who are willing to participate will be invited for an intake
visit at the hospital. During this intake, the eligibility of the
patients will be double-checked and there will be an op-
portunity for the patients to ask additional questions about
the study. Full written informed consent will be obtained
from each participating patient. Subsequently, the patients
will receive an interview and complete a set of question-
naires, which will result in the baseline measurement.
Ethical approval
The study protocol was approved by the Medical Ethical
Committee of the St. Elisabeth Hospital in Tilburg, The
Netherlands in August 2013 (reference number P1340).
The RCT has been registered under the trial number:
NL44692.008.13.
Randomization
After inclusion, every patient will be randomly assigned to
either the intervention or the care as usual group. Before
the start of the study, a list of 200 random numbers of 1
(intervention) or 2 (care as usual) will be created using
SPSS, version 21 (SPSS Inc,. Chicago, IL, USA). The ran-
dom numbers will be uniformly distributed. The list will
be kept at the secretary’s office of the outpatient neurology
clinic. At the end of the intake, a participant number will
be assigned to the patient. The secretary will refer to the
generated random list and inform the researcher to which
group the patient is allocated. The random list cannot be
edited and is concealed from the researcher. The above
described process of randomization will ensure objectivity
of the researcher and will eliminate bias in the partici-
pants’ group allocation.Blinding
Blinding of patients or practitioners is not possible due to
the current study design. As described previously, group
allocation will not be known to both the patient and
researcher during the intake. This allows for an objective
baseline measurement.
Intervention: Phystrac mechanical traction therapy
Patients in the intervention group will receive 12 treat-
ments (twice a week for a period of six weeks) with the
Phystrac mechanical traction device (type GR 10). The
Phystrac provides mechanical traction to the wrist using
weights between 1 and 18 kg. One treatment takes 10 to
15 minutes per diseased hand. The patient will be seated
beside the traction device on a seat that is adjustable in
height. The patient will put his arm on the arm support
of the device and will be secured with two Velcro straps;
one above and one below the elbow. Another Velcro
strap which is attached to the weights will be fastened
around the wrist with the palm of the hand upwards.
The weight is set at 5 kg for women and 7 kg for men
during the first treatment session. Every following treat-
ment session, the weight is increased by 1 kg for women
and 2 kg for men until 10 kg for women or 13 kg for
men, or until the mechanical traction becomes painful
or uncomfortable for the patient. When the patient is
fitted correctly, the weight will be lowered and provides
a pulling force on the wrist. After eight seconds the
weight is lifted, providing a rest period of four seconds.
This cycle will be repeated ten times. After 10 traction
movements, the device stops and the researcher will
rotate the wrist straps 30 degrees supination, after which
another 10 traction movements will be provided. After
that, a third set of 10 traction movements will be pro-
vided in 30 degrees pronation position. In total, 30 trac-
tion movements will be applied during each treatment.
During the six weeks of treatment, patients will not
receive other forms of treatment. After the six weeks of
treatment, patients are allowed to receive usual CTS
care when mechanical traction was not sufficient.
Control group: ‘care as usual’
The control group will receive ‘care as usual’, which
means they will receive regular treatment from their
usual health care provider. Patients may adopt an ex-
pectant approach or receive treatment in the form of
a wrist splint, local corticosteroid injections or CTR.
Forms of treatment received in both groups will be
documented during the full length of the study using
questionnaires and medical records.
Outcome measurements
Measurement time points and questionnaires used are
shown in Table 1. Data collection will take place at
Table 1 Measurements and time points
Measurement time points
Measure Questionnaire T0 V1 V2 T1 T2 T3
Patients’ background (demographics, clinical) - X X X X
CTS symptom severity and functional status BCTQ X X X X X X
Quality of life WHOQOL-BREF X X X X X
Depression and anxiety PHQ-4 X X X X X X
Health related resource utilization Non-standardized X X
Absenteeism from work Non-standardized X X X X
T0 = baseline, V1 = 3 weeks (only intervention group), V2 = 6 weeks (only invention group), T1 = 3 months, T2 = 6 months, T3 = 12 months, BCTQ = Boston Carpal
Tunnel Questionnaire, WHOQOL-BREF =World Health Organization Quality of Life questionnaire abbreviated version, PHQ-4 = Patient Health Questionnaire-4.
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and 12 months after baseline in both groups. Additional
data of the intervention group will be collected at two other
time points: at 3 weeks (after 6 treatments) and at 6 weeks
(after 12 treatments = immediately post-treatment). Infor-
mation about patient attendance and drop-out will be
recorded continuously. Patients of both groups will receive
the follow-up questionnaires at 3, 6 and 12 months via
Internet or a paper-and-pencil version with an addressed
return envelope, depending on the participant’s preference.
Primary outcome measure
Functional status and symptom severity
Self-reported functional status and symptom severity will
be measured using the BCTQ [21,22]. The BCTQ is a
disease-specific questionnaire referring to a typical 24-
hour period in the past two weeks. It consists of two
different scales: the Symptom Severity Scale (SSS) and the
Functional Status Scale (FSS). The SSS comprises 11 ques-
tions about symptom severity, while the FSS consists of 8
daily activities which are rated based on degree of diffi-
culty. The SSS and the FSS will be rated on a five-point
scale. Both scales result in mean scores between 1 and 5,
where greater impairment is represented by higher scores.
The BCTQ is responsive to clinically relevant change and
therefore an appropriate measure for treatment outcome
[21]. It has been validated and is used in multiple studies
to assess improvement in CTS symptoms over time [14],
and also in The Netherlands [13,23].
Secondary outcome measures
Quality of life
As a secondary outcome measure, self-reported quality of
life will be measured using the abbreviated Dutch version
of the World Health Organization Quality of Life (WHO-
QOL-BREF) [24,25]. The WHOQOL-BREF measures
quality of life in four domains: physical health, psycho-
logical health, social relationships, and environment. In
addition, it includes one facet on overall quality of life and
general health. The WHOQOL-BREF consists of 26 items
referring to the past two weeks, and which can be scoredon a five-point scale, where a higher score represents a
better quality of life. The WHOQOL-BREF has been
proven to be a valid and reliable instrument [24,25].Absenteeism from work
The number of days off work of each patient will be col-
lected using a non-standardized questionnaire. Further-
more, participants will be asked whether they are on
sick leave or have been because of their CTS complaints.Health care related resource utilization
Patients will be asked how many times they visited a pro-
fessional caregiver (general practitioner, physiotherapist,
psychologist, specialist, or other health care providers) in
the past 12 months, if they spent time in the hospital or
used medication via a non-standardized questionnaire.Tertiary outcome measures
Depression and anxiety
The four-item Patient Health Questionnaire (PHQ-4)
will be used to measure self-reported depression and
anxiety. The questionnaire consists of two items on de-
pression and two on anxiety, referring to the past two
weeks. A higher score represents a higher level of anx-
iety and depression. The PHQ-4 is a reliable instrument
that has been validated in a general population [26].Demographic and clinical variables
Demographic variables will be collected during the
intake interview. Information about age, education, job
status, nationality, residence, and marital status will be
documented. Also, BMI and life style habits (smoking,
alcohol intake, physical activity) will be documented at
baseline. Finally, clinical variables including medication
and the existence of co-morbidity (for example, diabetes,
cardiovascular disease, COPD) will be verified from the
patient’s medical record forms after obtaining written
informed consent.
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Sample size and power calculation
The sample size calculation is based on a clinically rele-
vant improvement from baseline on the functional and
symptom severity scores of the BCTQ after 12 months
follow-up. Sixty-four patients need to be included per
treatment arm to statistically detect a minimum effect
size of d = 0.5 between mean BCTQ scores of both
groups with a power of 0.8 and a two-sided alpha of
0.05. A total of 200 patients will be included (100 pa-
tients per treatment arm), taking into account possible
drop-out.
The following outcomes are defined. A completer is a
patient who participated in at least 70% of the interven-
tion sessions and the assessments. A responder is a
patient who will have a reduction of 0.74 of the mean
score (minimal clinical important difference) on the
BCTQ compared to baseline [21]. A drop-out is a
patient with less than 70% of the intervention or the
follow-up data.
Planned analyses
The baseline characteristics of those who complete and
will drop out during follow-up will be compared by
means of an independent t-test for continues data and
by Chi square analysis for categorical data. All analyses
will be based on the intention-to-treat principle. Linear
mixed effect models will be used to compare the change
from baseline at 12 months between groups on the
BCTQ, WHOQOL-BREF, absenteeism from work and
health related resource utilization. Linear mixed effect
models are able to adjust for missing values and are
therefore used to avoid loss of information [27]. The
baseline, three and six months measurements, as well as
duration of symptoms until inclusion, age, gender, and
co-morbidity will be included as covariates. Taking these
covariates into account will adjust for differences within
the groups and decrease variance. It will also adjust for
possible baseline differences between groups [28]. When
the data are normally distributed, Pearson’s correlation
coefficients will be generated to examine the relationship
between treatment outcome and depression and anxiety.
Discussion
This paper describes the design for an RCT with the
purpose to study the effectiveness of mechanical traction
as a treatment for CTS compared to care as usual. Re-
cruitment started in October 2013 in the VieCuri Med-
ical Center in Venlo, The Netherlands. The outpatient
neurology clinic registers over 400 CTS patients annu-
ally of whom about 350 will be eligible. During a period
of 12 months, these patients will be invited to participate
in the RCT. For several reasons, it is realistic to predict
a response rate of 60%. First, the new treatment ispainless and non-invasive. Second, in case of a non-
responder, the patient can always make a choice for
surgery without any evidence for poorer prognosis. The
predicted sample size of 200 patients will easily enable
the researchers in one year to include sufficient patients
into the trial with sufficient power. The clinical rele-
vance of this RCT is substantial. First, CTS is very com-
mon, not only in the general population (up to 4%), but
especially in the working population (up to 10%). Sec-
ondly, because the prevalence in the working population
is relatively high, CTS-related days of sick leave and
workers’ compensation lead to an economic burden. Ab-
senteeism from work after carpal tunnel release (CTR) is
on average two to seven weeks [29,30]. In the US, cumu-
lative excess loss of earnings of 4,443 workers who filed
a CTS related workers’ compensation claim was esti-
mated at $197 to $382 million over 6 years [31]. Thirdly,
the long-term benefits of current treatment strategies of
CTS are far from optimal. Fourth, it is well known that
recovery from pain symptoms can be mediated by the
patient’s mental state, especially anxiety and depression.
Pain is a process from nociceptive registration to a sub-
jective experience, which can be influenced by psycho-
logical wellbeing [32]. Depression has been reported as a
predictor of pain intensity in CTS patients [6]. Research
into the mediator effect of emotional distress on the out-
come of CTS treatment is limited. Hobby et al. reported
a significant association between BCTQ scores and
scores on the depression and anxiety scales [33]. More-
over, Lozano Calderon et al. reported that patient dissat-
isfaction and perceived impairment after CTR can partly
be predicted by depression [34]. Up until now, non-
invasive CTS treatment mostly consists of splint therapy
and corticosteroid injections. These treatments have not
been proven to be effective in the long-term [8-10]. In-
vasive CTR, on the other hand, results in a positive out-
come in only 70 to 75% of the patients in the long-term
[16,17]. Mechanical traction using the Phystrac traction
device is a promising treatment option. It is non-invasive
and has been reported to result in substantial symptom re-
lief in 70% of the patients, and in 60% of the patients two
years post-treatment [19,20]. However, there is no conclu-
sive scientific evidence for the effectiveness of mechanical
traction. Therefore, there is a clear need for an RCT to
compare mechanical traction to regular treatment options,
such as splint therapy, steroid injections, and CTR. Im-
provements in functional status and symptom severity will
be measured using the BCTQ. This questionnaire has
been proven to be a valid and reliable outcome measure
[21,22]. It is widely used in clinical practice to evaluate the
recovery of CTS symptoms after treatment. This means
that we have an easy, user-friendly, and quick measure
to assess clinical outcome. One strength of this study is
the additional outcome measures. Apart from clinical
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health related resource utilization will be measured. An-
other strength of this study is the follow-up length. Many
studies only include a few weeks or months follow-up,
while the current study aims at a 12 months follow-up
period. A possible limitation of this study is the heterogen-
eity of the care as usual group. The patients in this group
can receive different forms of treatment or no treatment at
all. However, since this represents the general practice in
an outpatient neurology clinic, the results of this RCT will
provide clinically relevant information.
Since the current treatment options are not effective
in all patients, or only short-term, research into an alter-
native, long-term effective treatment option will be of
great clinical value. The proposed RCT will provide pos-
sible evidence for mechanical traction as a new non-
invasive treatment for CTS. Since 4% of the general
population develops CTS, the results of this trial will be
of benefit to a large patient population. Surgery is often
considered a last resort and many patients postpone it
for as long as possible, resulting in irreversible nerve
damage in some cases. Furthermore, contrary to CTR,
mechanical traction does not interfere with work or
other daily activities. A less invasive treatment may also
have a positive influence on quality of life. Therefore,
mechanical traction provides a safe treatment option as
an alternative to usual care.
Trial status
Inclusion has started October 2013. Inclusion is estimated
to take up to a year, with one year follow-up. Final results
are expected end of 2015.
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